Artiva Biotherapeutics Inc.

ARTV | NASDAQ

Price Alert Chart Builder DCF Calculator

$7.83

-$0.78 (-9.06%)

At close: Sep 21, 2026, 4:00 PM ET

$7.80

-$0.03 (-0.38%)

Pre-market: Sep 22, 2026, 4:00 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $420.94M

Enterprise Value $43.26M

Beta 2.20

Average Volume 509.7K

Shares Outstanding (Diluted) 39.41M

Shares Change YoY 61.67%

Institutional Ownership 68.22%

Exchange NASDAQ

ISIN US04317A1079

Price Performance

Price Change 1M -27.7%

Price Change 3M -20.1%

Price Change 6M 43.4%

Price Change YTD 85.1%

Price Change 1Y 190.0%

Price Change 3Y -34.8%

Price Change 5Y -34.8%

1M CAGR (ann.) -25.6%

1Y CAGR (ann.) 277.6%

5Y CAGR (ann.) N/A

All-Time CAGR -14.2%

Valuation

PE Ratio -2.37

Forward PE N/A

PEG Ratio -0.79

Forward PEG -0.61

PS Ratio N/A

Forward PS N/A

PB Ratio 1.10

P/FCF Ratio -3.90

P/Adj. FCF Ratio -3.60

P/OCF Ratio -3.21

EV/Sales N/A

EV/EBIT -0.48

EV/EBITDA -0.49

EV/FCF -0.44

Earnings Yield -42.3%

FCF Yield -25.6%

Adj. FCF Yield -27.8%

Financial Health

Net Cash $349.39M

Total Debt $9.85M

Cash & Short-Term Investments $349.39M

Total Assets $368.63M

Current Ratio 24.16

Quick Ratio 24.16

Debt / Equity Ratio 0.03

Debt / EBITDA -0.11

Debt / FCF -0.10

OCF / Debt -9.77

Interest Coverage 0.00

Altman Z-Score 10.80

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -8.4%

Returns

Return on Assets -24.6%

Return on Equity -53.9%

Return on Invested Capital -26.9%

Return on Capital Employed -27.2%

Return on Tangible Assets -24.6%

Historical Growth (CAGR)

Revenue CAGR 3Y -150.0%

Revenue CAGR 5Y -10.7%

Revenue CAGR 10Y N/A

EPS CAGR 3Y -36.1%

EPS CAGR 5Y -1.7%

EPS CAGR 10Y N/A

FCF CAGR 3Y -31.7%

FCF CAGR 5Y -23.7%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 4

EPS Growth Next 3Y 7.5%

Revenue Growth Next 3Y N/A

Earnings Date Nov 10, 2026

EPS Estimate (next Q) -$0.54

EPS Growth Est (next Q) -38.6%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $37.50

Price Target Upside 378.9%

Cash Flow

Operating Cash Flow $-96.18M

Free Cash Flow $-98.1M

Adj. Free Cash Flow $-106.37M

FCF Per Share -$2.49

OCF Per Share -$2.44

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-666K

Operating Income $-96.15M

EBITDA $-87.47M

Net Income $-90.82M

EPS (Diluted) -$3.31

Revenue / Employee N/A

Profit / Employee $-789.75K

Employees 115